October 29 | 2021 2cureX – Banbrytande cancerbehandlingstest rullas ut – Mangold Insight Analys Read more
October 15 | 2021 2cureX successfully completed the EU-project MicroCaT and received the final financial tranche of a 3,0 MEUR grant. Read more
October 12 | 2021 2cureX provides commercial goals for 2022 at Live Strategy Update on the 12th of October 2021. Read more
October 8 | 2021 2cureX provides a Live Strategy Update on the company’s product portfolio and commercialization strategy on the 12th of October 2021. Read more
September 28 | 2021 Specialized diagnostic solutions leader Werfen, to distribute 2cureX products in Spain Read more
August 26 | 2021 2cureX offentliggör delårsrapport för det andra kvartalet och första halvåret 2021 Read more
August 26 | 2021 2cureX publishes interim report for the second quarter and first half of 2021 Read more
August 20 | 2021 New development of the IndiTreat® technology allows prediction of response to anti-angiogenic drugs in colorectal cancer. Read more
July 29 | 2021 2cureX appoints two internationally highly recognized oncologists as Clinical Advisors Read more
July 1 | 2021 2cureX and University Hospital of Hamburg-Eppendorf present IndiTreat data at ESMO GI for early-stage Pancreatic Cancer Read more
June 7 | 2021 ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients Read more
June 1 | 2021 Management exercise all warrants within the framework of the 2018 incentive program Read more